Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
European Journal of Cancer2019Vol. 119, pp. 168–178
Citations Over TimeTop 10% of 2019 papers
Paul Nathan, Paolo A. Ascierto, John B.A.G. Haanen, Enrique Espinosa, Lev Demidov, Claus Garbe, Michele Guida, Paul Lorigan, Vanna Chiarion‐Sileni, Helen Gogas, Michele Maio, Maria Teresa Fierro, Christoph Höeller, Patrick Terheyden, Ralf Gutzmer, Tormod Kyrre Guren, Dimitrios Bafaloukos, Piotr Rutkowski, Ruth Plummer, Ashita Waterston, Martin Kaatz, Mario Mandalà, Iván Márquez‐Rodas, Eva Muñoz‐Couselo, Reinhard Dummer, E. Grigoryeva, Tina C. Young, Dirk Schadendorf
Related Papers
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)
- → TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab(2024)